Losartan and acute kidney injury
Pro Research Analysisby 
Searched over 200M research papers
Losartan and Acute Kidney Injury: Protective Mechanisms and Clinical Implications
Introduction to Acute Kidney Injury (AKI) and Losartan
Acute kidney injury (AKI) is a significant clinical problem characterized by a sudden decline in kidney function, often leading to chronic kidney disease (CKD) if not managed properly. Losartan, an angiotensin II receptor blocker (ARB), has been studied extensively for its potential protective effects against AKI. This article synthesizes current research on the role of losartan in mitigating AKI and its progression to CKD.
Losartan's Protective Effects in Ischemia/Reperfusion Injury
Ischemia/reperfusion (I/R) injury is a common cause of AKI. Research indicates that losartan can significantly reduce kidney damage caused by I/R. In a study involving male Wistar rats, losartan administration before and after I/R injury decreased serum levels of urea nitrogen, creatinine, and other markers of kidney damage. This suggests that losartan, possibly in combination with angiotensin 1-7, can protect the kidneys from I/R-induced damage by reducing oxidative stress and improving antioxidant capacity .
Losartan and Renal Hemodynamics in Hypotension
Hypotensive events during surgery are a known risk factor for AKI. A study on pigs demonstrated that pre-treatment with losartan improved renal blood flow (RBF) and renal oxygen delivery (RDO2) after propofol-induced hypotension. This indicates that losartan can mitigate the adverse effects of anesthesia-induced hypotension on kidney function by preventing angiotensin II-mediated renal vasoconstriction .
Prevention of AKI to CKD Transition
One of the critical challenges in AKI management is preventing its progression to CKD. Studies in murine models have shown that losartan can significantly reduce the risk of CKD following AKI. Losartan administration post-AKI was found to lower mortality, blood pressure, albuminuria, and kidney fibrosis, suggesting that it can interrupt the maladaptive processes that lead to CKD Cheng2016Rodríguez-Romo2016. This protective effect is attributed to improved renal blood flow recovery, reduced inflammation, and enhanced expression of protective factors like hypoxia-inducible factor 1α .
Losartan in Sepsis-Induced AKI
Sepsis is another major cause of AKI, often leading to increased kidney blood flow despite reduced glomerular filtration. Research indicates that sepsis reduces angiotensin type-1 receptor (AT1R) expression, exacerbating kidney dysfunction. Losartan, by blocking AT1R, was found to worsen sepsis-induced changes in kidney function, suggesting that careful consideration is needed when using ARBs in septic patients .
Comparative Efficacy of Losartan and Captopril
Both losartan and captopril, another RAAS inhibitor, have been shown to attenuate drug-induced AKI. While captopril was superior in normalizing certain kidney injury markers, losartan was more effective in improving glomerular filtration rate (GFR). This indicates that both drugs have their unique benefits and can be chosen based on specific clinical needs Zafar2018Amin2017.
Molecular Mechanisms: Role of Circular RNAs
Recent studies have explored the molecular mechanisms underlying losartan's protective effects. In a rat model of I/R-induced AKI, losartan was found to modulate the expression of circular RNAs (circRNAs) associated with various biological processes, including the PI3K-Akt signaling pathway. This suggests that losartan's renoprotective effects may involve complex regulatory networks at the molecular level .
Conclusion
Losartan has demonstrated significant potential in protecting against AKI and preventing its progression to CKD. Its benefits include reducing oxidative stress, improving renal hemodynamics, and modulating molecular pathways involved in kidney injury. However, its use in specific conditions like sepsis requires careful consideration. Further research is needed to fully understand the mechanisms and optimize the clinical use of losartan in AKI management.
Sources and full results
Most relevant research papers on this topic